Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation

被引:102
作者
Yoshida, Tatsuya [1 ,2 ,3 ]
Ishii, Genichiro [1 ]
Goto, Koichi [2 ]
Neri, Shinya [1 ]
Hashimoto, Hiroko [1 ]
Yoh, Kiyotaka [2 ]
Niho, Seiji [2 ]
Umemura, Shigeki [2 ]
Matsumoto, Shingo [2 ]
Ohmatsu, Hironobu [2 ]
Iida, Shinsuke [3 ]
Niimi, Akio [3 ]
Nagai, Kanji [2 ]
Ohe, Yuichiro [2 ]
Ochiai, Atsushi [1 ]
机构
[1] Natl Canc Ctr Hosp East, Div Pathol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba 2778577, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi, Japan
关键词
TYROSINE KINASE INHIBITORS; PREDICTS POOR-PROGNOSIS; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; OPEN-LABEL; GEFITINIB; GROWTH; CHEMOTHERAPY; STROMA; POLYMORPHISM;
D O I
10.1158/1078-0432.CCR-14-0846
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The biologic characteristics of microenvironmental constituents, especially cancer-associated fibroblasts (CAF), can be key regulators of the cellular sensitivity to molecular-targeted therapy. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have marked therapeutic effects against non-small cell lung cancer (NSCLC) with EGFR mutations, but some patients have exhibited primary resistance to EGFR-TKIs. We recently reported that podoplanin-positive fibroblasts are associated with a tumor-promoting phenotype of CAFs in lung adenocarcinoma. The aim of this study was to evaluate whether the susceptibility of NSCLC to EGFR-TKIs could be affected by podoplanin-expressing CAFs. Experimental Design: We evaluated the EGFR-TKI sensitivity of EGFR-mutant lung adenocarcinoma cell lines cocultured with podoplanin-expressing CAFs. We also examined the association between the expression of podoplanin in CAFs in surgical specimens and EGFR-TKI response of postoperative recurrent patients with EGFR mutations (N = 106). Results: Lung adenocarcinoma cell lines became more resistant to EGFR-TKI when cocultured with podoplanin-expressing CAFs, compared with control CAFs in vitro. The knockdown of podoplanin expression on CAFs cancelled the resistance to EGFR-TKIs in cancer cells. Compared with control CAFs, the cancer cells that were cocultured with podoplanin-positive CAFs continued to exhibit significantly higher p-ERK levels after treatment with gefitinib. Furthermore, postoperative recurrent patients with podoplanin-positive CAFs had a significantly lower overall response rate to EGFR-TKIs compared with those with podoplanin-negative CAFs (53% vs. 83%; P < 0.01). Conclusions: Podoplanin-positive CAFs play an important role in primary resistance to EGFR-TKIs and may be an ideal therapeutic target for use in combination therapy with EGFR-TKIs. (C) 2014 AACR.
引用
收藏
页码:642 / 651
页数:10
相关论文
共 50 条
[31]   Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance [J].
Li, Fang ;
Zhu, Tengjiao ;
Cao, Baoshan ;
Wang, Jiadong ;
Liang, Li .
EUROPEAN JOURNAL OF CANCER, 2017, 84 :184-192
[32]   An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer [J].
Qi, Yuexiao ;
Xia, Xiaojun ;
Shao, Lihua ;
Guo, Liyun ;
Dong, Yumei ;
Tian, Jinhui ;
Xu, Lijun ;
Niu, Ruijun ;
Wei, Shihong .
FRONTIERS IN ONCOLOGY, 2022, 12
[33]   First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? [J].
Takeda, Masayuki ;
Nakagawa, Kazuhiko .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (01)
[34]   Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer [J].
Hu, Wentao ;
Liu, Yahui ;
Chen, Jian .
ONCOTARGET, 2017, 8 (15) :25046-25054
[35]   Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer [J].
Wang, Yuyan ;
Duan, Jianchun ;
Chen, Hanxiao ;
Bai, Hua ;
An, Tongtong ;
Zhao, Jun ;
Wang, Zhijie ;
Zhuo, Minglei ;
Wang, Shuhang ;
Wang, Jie .
ONCOLOGY LETTERS, 2017, 13 (04) :2425-2431
[36]   Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance [J].
Han, Ruoshuang ;
Jia, Yijun ;
Li, Xuefei ;
Zhao, Chao ;
Zhao, Sha ;
Liu, Sangtian ;
Liu, Yiwei ;
Chen, Donglai ;
Zhang, Qian ;
Liu, Xiaozhen ;
Shi, Jinpeng ;
Li, Jiayu ;
Zhou, Caicun .
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (03) :1277-1291
[37]   Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer [J].
Wang, Xiaohong ;
Liu, Yonggang ;
Meng, Zhiying ;
Wu, Yun ;
Wang, Shubin ;
Jin, Gaowa ;
Qin, Yingchun ;
Wang, Fengyun ;
Wang, Jing ;
Zhou, Haifei ;
Su, Xiaoxing ;
Fu, Xiuhua ;
Wang, Xiaolan ;
Shi, Xiaoyu ;
Wen, Zhenping ;
Jia, Xiaoqiong ;
Qin, Qiong ;
Gao, Yongqiang ;
Guo, Weidong ;
Lu, Shun .
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
[38]   First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice? [J].
Wang, Shuyun ;
Gao, Aiqin ;
Liu, Jie ;
Sun, Yuping .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (03) :443-453
[39]   The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs [J].
Gu, Weiguo ;
Liu, Penghui ;
Tang, Jiaming ;
Lai, Jianfei ;
Wang, Siya ;
Zhang, Jiaming ;
Xu, Jinbiao ;
Deng, Jianxiong ;
Yu, Feng ;
Shi, Chao ;
Qiu, Feng .
FRONTIERS IN ONCOLOGY, 2024, 13
[40]   AFATINIB IN EGFR MUTANT NON-SMALL-CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO REVERSIBLE EGFR-TKIS [J].
Cappuzzo, Federico ;
Tiseo, Marcello ;
Chiari, Rita ;
Landi, Lorenza ;
Ricciardi, Serena ;
Rossi, Elisa ;
Galetta, Domenico ;
Novello, Silvia ;
Milella, Michele ;
D'Incecco, Armida ;
Haspinger, Eva Regina ;
Cortinovis, Diego ;
Santo, Antonio ;
Banna, Giuseppe ;
Facchi-Netti, Francesco ;
Levra, Matteo Giaj ;
Vari, Sabrina ;
Crino, Lucio ;
De Marinis, Filippo .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S610-S610